MEDEZE-R Stock Overview

Engages in collection and storage of stem cells for use in medication in Thailand, Vietnam, Cambodia, and internationally. More details

MEDEZE-R fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	4/6
Past Performance	6/6
Financial Health	5/6
Dividends	1/6

Rewards

Earnings are forecast to grow 24.41% per year

Earnings grew by 36.1% over the past year

Risk Analysis

Highly volatile share price over the past 3 months compared to the TH market

My Notes

Capture your thoughts, links and company narrative

Medeze Group Public Company Limited Competitors

Klinique Medical Clinic

SET:KLINIQ

฿7.2b

Safe Fertility Group

SET:SAFE

฿4.0b

Genesis Fertility Center

SET:GFC

฿1.5b

Dental Corporation

SET:D

฿1.0b

Price History & Performance

Summary of share price highs, lows and changes for Medeze Group
Historical stock prices
Current Share Price	฿8.90
52 Week High	฿12.00
52 Week Low	฿6.60
Beta	0
1 Month Change	14.84%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-19.82%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	MEDEZE-R	TH Healthcare	TH Market
7D	29.0%	1.1%	0.9%
1Y	n/a	-16.3%	-1.7%

Return vs Industry: Insufficient data to determine how MEDEZE-R performed against the TH Healthcare industry.

Return vs Market: Insufficient data to determine how MEDEZE-R performed against the TH Market.

Price Volatility

Is MEDEZE-R's price volatile compared to industry and market?
MEDEZE-R volatility
MEDEZE-R Average Weekly Movement	11.1%
Healthcare Industry Average Movement	4.0%
Market Average Movement	4.3%
10% most volatile stocks in TH Market	8.9%
10% least volatile stocks in TH Market	2.1%

Stable Share Price: MEDEZE-R's share price has been volatile over the past 3 months compared to the TH market.

Volatility Over Time: Insufficient data to determine MEDEZE-R's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2010	n/a	Veerapol Khemarangsan	www.medezegroup.com

Medeze Group Public Company Limited engages in collection and storage of stem cells for use in medication in Thailand, Vietnam, Cambodia, and internationally. The company operates through four segments: Stem Cells; Natural Killer Cells; Others; and Sales of Products. It also provides sorting, cultivation, and development of stem cells; testing services to test the performance and count the number of natural killer cells; and research, develops, and collects data on all types of human cellular activities and medical laboratory test.

Medeze Group Public Company Limited Fundamentals Summary

How do Medeze Group's earnings and revenue compare to its market cap?
MEDEZE-R fundamental statistics
Market cap	฿9.51b
Earnings (TTM)	฿295.59m
Revenue (TTM)	฿823.42m

32.2x

P/E Ratio

11.5x

P/S Ratio

Is MEDEZE-R overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
MEDEZE-R income statement (TTM)
Revenue	฿823.42m
Cost of Revenue	฿173.12m
Gross Profit	฿650.29m
Other Expenses	฿354.70m
Earnings	฿295.59m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	0.28
Gross Margin	78.97%
Net Profit Margin	35.90%
Debt/Equity Ratio	0%

How did MEDEZE-R perform over the long term?

See historical performance and comparison

Dividends

1.8%

Current Dividend Yield

184%

Payout Ratio

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/30 12:42
End of Day Share Price	2024/12/30 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Medeze Group Public Company Limited is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Wilasinee Boonmasungsong	Globlex Securities Co. Ltd.
Thakol Banjongruck	Yuanta Securities (Thailand) Company Limited